Stock ZEAL ZEALAND PHARMA A/S
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Company Zealand Pharma A/S Nasdaq

Equities

ZEAL

US98920Y3045

Biotechnology & Medical Research

Business Summary

Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.

At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.

Number of employees: 270

Sales per Business

DKK in Million2022Weight2023Weight Delta
Peptide-based Medicines
100.0 %
104 100.0 % 343 100.0 % +229.65%

Sales per region

DKK in Million2022Weight2023Weight Delta
Germany
85.9 %
-- 294,509 85.9 % -
Denmark
12.9 %
35 33.7 % 44,185 12.9 % +126,142.86%
United States
1.2 %
69 66.3 % 4,094 1.2 % +5,833.33%

Managers

Managers TitleAgeSince
Adam Sinding Steensberg CEO
 Chief Executive Officer 50 31/12/09
Henriette Wennicke DFI
 Director of Finance/CFO - 31/10/22
Ivan M. Møller COO
 Chief Operating Officer 52 28/02/18
David M. Kendall CTO
 Chief Tech/Sci/R&D Officer 62 01/06/22
Frederik Barfoed Beck BRD
 Director/Board Member 57 -
Anna Krassowska IRC
 Investor Relations Contact - -
Ravinder Chahil LAW
 General Counsel 56 -
Christina Sonnenborg Bredal HRO
 Human Resources Officer 39 31/12/19

Members of the board

Members of the board TitleAgeSince
Leonard Kruimer BRD
 Director/Board Member 66 03/04/19
Alf Gunnar Martin Nicklasson CHM
 Chairman 69 31/12/14
Kirsten Drejer BRD
 Director/Board Member 68 18/04/18
Jeffrey Berkowitz BRD
 Director/Board Member 58 03/04/19
Bernadette Connaughton BRD
 Director/Board Member 65 03/04/19
Frederik Barfoed Beck BRD
 Director/Board Member 57 -
Anneline Nansen BRD
 Director/Board Member 55 31/08/21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 62,626,184 62,176,860 ( 99.28 %) 351,307 ( 0.5610 %) 99.28 %

Shareholders

NameEquities%Valuation
Van Herk Investments BV
9.950 %
6,233,183 9.950 % 566 M $
Polar Capital LLP
9.015 %
5,647,561 9.015 % 513 M $
J.O. Hambro Capital Management Ltd.
4.993 %
3,128,162 4.993 % 284 M $
MP Investment Management A/S
4.173 %
2,614,590 4.173 % 237 M $
Nykredit Bank A/S (Investment Management)
0.9496 %
594,915 0.9496 % 54 M $
ZEALAND PHARMA A/S
0.5956 %
373,134 0.5956 % 34 M $
Fundamental Fondsmæglerselskab A/S
0.4954 %
310,340 0.4954 % 28 M $
Amundi Asset Management SA (Investment Management)
0.4896 %
306,722 0.4896 % 28 M $
Danske Bank A/S (Investment Management)
0.4411 %
276,337 0.4411 % 25 M $
Banque Internationale À Luxembourg SA (Denmark)
0.4378 %
274,263 0.4378 % 25 M $

Holdings

NameEquities%Valuation
ZEALAND PHARMA A/S
0.60%
 373,134 0.60% 33,861,213 $

Company contact information

Zealand Pharma A/S

Sydmarken 11

2860, Soborg

+45 88 77 36 00

http://www.zealandpharma.com
address Zealand Pharma A/S(ZEAL)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+11.91% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.60% 106B
BIONTECH SE Stock BioNTech SE
-4.68% 24.28B
ARGENX SE Stock argenx SE
-0.82% 21.96B
GENMAB A/S Stock Genmab A/S
-10.12% 18.16B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.12% 16.37B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.47% 15.56B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.77% 13.63B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+34.58% 12.27B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ZEAL Stock
  4. ZEAL Stock
  5. Company Zealand Pharma A/S